Skip to main content

First-Quarter 2022 Business Review

Marcy l’Étoile (France), April 11th, 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2022.

  • First-quarter organic growth of -4.5% at constant exchange rates and scope of consolidation:
    • €837 million in sales
    • Down 0.9% as reported
  • Solid +6% growth in Industrial Applications and +5% growth in Microbiology
  • Stable sales of BIOFIRE® panels, in line with expectations for the quarter
  • Anticipated headwinds in Immunoassays with lower COVID-related assays demand


“In a continued highly uncertain business environment, our first quarter performance is aligned with our outlook. Sales growth was particularly solid in both microbiology and industrial applications, and in line with our expectations on molecular biology and immunoassays.”

Alexandre Mérieux, Chairman and Chief Executive Officer

Read the full press release

20220411PR - bioMérieux - Sales Q1 2022.pdf
352 KB